Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 9 studies | 30% ± 16% | |
peripheral blood | 8 studies | 29% ± 16% | |
lung | 8 studies | 26% ± 5% | |
intestine | 7 studies | 24% ± 11% | |
eye | 5 studies | 22% ± 6% | |
liver | 4 studies | 27% ± 16% | |
adipose | 4 studies | 18% ± 2% | |
kidney | 3 studies | 22% ± 3% | |
bone marrow | 3 studies | 19% ± 5% | |
breast | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 14158.75 | 1445 / 1445 | 100% | 11.88 | 183 / 183 |
ovary | 100% | 16508.62 | 180 / 180 | 100% | 16.50 | 428 / 430 |
brain | 100% | 15392.63 | 2640 / 2642 | 98% | 16.24 | 690 / 705 |
stomach | 100% | 12307.19 | 359 / 359 | 98% | 9.46 | 279 / 286 |
bladder | 100% | 14622.19 | 21 / 21 | 97% | 12.24 | 491 / 504 |
uterus | 100% | 19971.33 | 170 / 170 | 96% | 12.30 | 439 / 459 |
thymus | 100% | 20626.62 | 653 / 653 | 95% | 10.98 | 574 / 605 |
prostate | 100% | 19263.38 | 245 / 245 | 94% | 11.39 | 471 / 502 |
pancreas | 100% | 7655.24 | 328 / 328 | 94% | 10.71 | 167 / 178 |
intestine | 100% | 16658.99 | 966 / 966 | 94% | 9.46 | 494 / 527 |
breast | 100% | 13282.66 | 459 / 459 | 93% | 9.28 | 1036 / 1118 |
adrenal gland | 100% | 16457.41 | 258 / 258 | 92% | 8.10 | 212 / 230 |
lung | 100% | 13334.69 | 578 / 578 | 89% | 9.34 | 1023 / 1155 |
skin | 100% | 11811.01 | 1809 / 1809 | 81% | 7.29 | 384 / 472 |
liver | 100% | 10209.18 | 226 / 226 | 80% | 6.14 | 323 / 406 |
kidney | 100% | 16162.66 | 89 / 89 | 76% | 8.22 | 687 / 901 |
adipose | 100% | 12131.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 17833.62 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 9.26 | 1 / 1 |
blood vessel | 100% | 10998.19 | 1334 / 1335 | 0% | 0 | 0 / 0 |
heart | 100% | 8087.34 | 858 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 6761.70 | 796 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 97% | 8183.62 | 898 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 10.14 | 28 / 29 |
tonsil | 0% | 0 | 0 / 0 | 82% | 6.83 | 37 / 45 |
eye | 0% | 0 | 0 / 0 | 65% | 6.07 | 52 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_1904247 | Biological process | positive regulation of polynucleotide adenylyltransferase activity |
GO_0006397 | Biological process | mRNA processing |
GO_0006936 | Biological process | muscle contraction |
GO_0016973 | Biological process | poly(A)+ mRNA export from nucleus |
GO_0000165 | Biological process | MAPK cascade |
GO_0006396 | Biological process | RNA processing |
GO_0042405 | Cellular component | nuclear inclusion body |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_1990904 | Cellular component | ribonucleoprotein complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0070063 | Molecular function | RNA polymerase binding |
GO_0008143 | Molecular function | poly(A) binding |
GO_0005515 | Molecular function | protein binding |
GO_0003723 | Molecular function | RNA binding |
Gene name | PABPN1 |
Protein name | Polyadenylate-binding protein 2 (PABP-2) (Poly(A)-binding protein 2) (Nuclear poly(A)-binding protein 1) (Poly(A)-binding protein II) (PABII) (Polyadenylate-binding nuclear protein 1) Poly(A) binding protein nuclear 1 Poly(A) binding protein nuclear 1 (cDNA FLJ57714, highly similar to Poly(A)-binding protein 2) |
Synonyms | PABP2 PAB2 |
Description | FUNCTION: Involved in the 3'-end formation of mRNA precursors (pre-mRNA) by the addition of a poly(A) tail of 200-250 nt to the upstream cleavage product (By similarity). Stimulates poly(A) polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation reaction and controls also the poly(A) tail length (By similarity). Increases the affinity of poly(A) polymerase for RNA (By similarity). Is also present at various stages of mRNA metabolism including nucleocytoplasmic trafficking and nonsense-mediated decay (NMD) of mRNA. Cooperates with SKIP to synergistically activate E-box-mediated transcription through MYOD1 and may regulate the expression of muscle-specific genes . Binds to poly(A) and to poly(G) with high affinity (By similarity). May protect the poly(A) tail from degradation (By similarity). Subunit of the trimeric poly(A) tail exosome targeting (PAXT) complex, a complex that directs a subset of long and polyadenylated poly(A) RNAs for exosomal degradation. The RNA exosome is fundamental for the degradation of RNA in eukaryotic nuclei. Substrate targeting is facilitated by its cofactor MTREX, which links to RNA-binding protein adapters . . |
Accessions | H0YJH9 ENST00000556821.5 Q86U42 ENST00000557702.5 G3V4T2 B4DEH8 ENST00000216727.9 [Q86U42-1] ENST00000397276.6 [Q86U42-2] ENST00000555295.1 |